TABLE 1.
Correlation analyzed between SPP1 expression and clinicopathologic characteristics in cervical cancer based on TCGA database.
| Characteristic | Low expression of SPP1 | High expression of SPP1 | p value |
|---|---|---|---|
| N | 153 | 153 | |
| T stage, n (%) | 0.020 | ||
| T1 | 82 (33.7%) | 58 (23.9%) | |
| T2 | 31 (12.8%) | 41 (16.9%) | |
| T3 | 6 (2.5%) | 15 (6.2%) | |
| T4 | 4 (1.6%) | 6 (2.5%) | |
| N stage, n (%) | 0.243 | ||
| N0 | 73 (37.4%) | 61 (31.3%) | |
| N1 | 27 (13.8%) | 34 (17.4%) | |
| M stage, n (%) | 0.699 | ||
| M0 | 55 (43.3%) | 61 (48%) | |
| M1 | 4 (3.1%) | 7 (5.5%) | |
| Clinical stage, n (%) | 0.020 | ||
| Stage I | 95 (31.8%) | 67 (22.4%) | |
| Stage II | 30 (10%) | 39 (13%) | |
| Stage III | 17 (5.7%) | 29 (9.7%) | |
| Stage IV | 9 (3%) | 13 (4.3%) | |
| Radiation therapy, n (%) | 0.726 | ||
| No | 63 (20.6%) | 59 (19.3%) | |
| Yes | 90 (29.4%) | 94 (30.7%) | |
| Primary therapy outcome, n (%) | 0.106 | ||
| PD | 7 (3.2%) | 16 (7.3%) | |
| SD | 2 (0.9%) | 4 (1.8%) | |
| PR | 4 (1.8%) | 4 (1.8%) | |
| CR | 101 (46.1%) | 81 (37%) | |
| Race, n (%) | 0.444 | ||
| Asian | 12 (4.6%) | 8 (3.1%) | |
| Black or African American | 13 (5%) | 18 (6.9%) | |
| White | 106 (40.6%) | 104 (39.8%) | |
| Histologic type, n (%) | <0.001 | ||
| Adenosquamous | 40 (13.1%) | 13 (4.2%) | |
| Squamous cell carcinoma | 113 (36.9%) | 140 (45.8%) | |
| Histologic grade, n (%) | 0.954 | ||
| G1 | 10 (3.6%) | 9 (3.3%) | |
| G2 | 69 (25.2%) | 66 (24.1%) | |
| G3 | 62 (22.6%) | 57 (20.8%) | |
| G4 | 0 (0%) | 1 (0.4%) | |
| Age (years), median (IQR) | 45 (37, 54) | 49 (40, 60) | 0.038 |